Physician profile
Thomas S Parisi
NPI 1275587677
$2,776.91
in general payments reported to CMS, 2019-2025
29 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $839 · 2021: $338 · 2022: $456 · 2023: $281 · 2024: $188 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595 · Education: $45.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.53 |
| Education | $45.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $499.30 | 2019-2021 | |
| Tactile Systems Technology INC | $484.42 | 2019-2024 | Entre Plus, Flexitouch Plus |
| Bard Peripheral Vascular, INC. | $212.08 | 2021-2023 | Venclose Maven Catheter |
| Abbvie INC. | $199.98 | 2021-2025 | |
| Abbott Laboratories | $172.95 | 2019 | |
| Paratek Pharmaceuticals, INC. | $150.72 | 2020-2021 | |
| Medtronic, INC. | $147.97 | 2022 | |
| Boston Scientific Corporation | $138.17 | 2020-2025 | Varithena Administration Pack |
| Janssen Pharmaceuticals, INC | $118.10 | 2019-2023 | Xarelto |
| Mimedx Group, INC. | $108.37 | 2024-2025 | |
| Novo Nordisk INC | $77.37 | 2020-2024 | Ozempic, Rybelsus |
| Allergan, INC. | $69.89 | 2019-2020 | |
| Pfizer INC. | $65.13 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $46.21 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.87 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $25.80 | 2021-2022 | |
| Misonix INC | $23.36 | 2020 | |
| Bioventus LLC | $23.20 | 2022 | |
| Lucid Diagnostics INC. | $22.54 | 2022 | |
| Solventum Corporation | $18.99 | 2025 | |
| Dexcom, INC. | $18.18 | 2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $18.11 | 2022 | |
| Medtronic Vascular, INC. | $17.88 | 2020 | |
| Glaxosmithkline, LLC. | $17.88 | 2023 | Arexvy |
| Gilead Sciences, INC. | $16.61 | 2020 | |
| Organogenesis INC. | $16.60 | 2019 | |
| Bardy Diagnostics, INC. | $15.95 | 2022 | |
| Merck Sharp & Dohme LLC | $12.98 | 2020 | |
| Biowound Solutions, INC. | $9.30 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Parisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.